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DES for Repeat
Revascularization in
Patients With Isolated
Proximal LAD Disease?We read with great interest the paper by Hannan
et al. (1) comparing the clinical outcomes in alarge number of patients with isolated proximal
left anterior descending (PLAD) coronary artery
disease who underwent coronary artery bypass
graft (CABG) surgery and percutaneous coronary
interventions (PCIs) with drug-eluting stents (DES).
They showed that there were no statistically sig-
niﬁcant differences in mortality or mortality, myo-
cardial infarction (MI), and/or stroke between the
CABG and PCI-DES groups, whereas CABG patients
had signiﬁcantly lower repeat revascularization
rates.
Despite the important ﬁndings of the study, there
are some concerns for the clinical application of
these results. First, the type of DES used in the
PCI-DES group was not clariﬁed. New-generation
DES have been proved more effective and safer
than ﬁrst-generation drug-eluting or bare metal
stents (2). Considering this superiority of second-
generation DES, it would be appropriate for study
results to be adjusted for stent type/stent genera-
tion (3).
A study by our group compared the outcomes in
patients with isolated PLAD coronary artery disease
who underwent CABG and PCI with ﬁrst-generation
DES (4). This study showed that there were no
statistically signiﬁcant differences in major adverse
cardiac events (MACE), all-cause mortality, cardiac
death, myocardial infarction, and target vessel revas-
cularization between the 2 groups.
Another issue that emerges from the paper is
the deﬁnition of the endpoints. The use of all-cause
mortality but not cardiac death and stroke or MI
in the complex index of MI/mortality/stroke in
the unmatched patients and propensity-matched
patients analysis may differentiate the ﬁnal results.
Indeed, in the analysis of patients without a previ-
ous MI, when the authors add MI and stroke to the
all-cause mortality, the complex index tends to be
statistically signiﬁcant in favor of CABG (adjusted
hazard ratio: 0.96; 95% conﬁdence interval: 0.86
to 1.06). A table showing the adjusted hazard
ratios for MI, cardiac death, and stroke separately is
needed (5).
The comparison of CABG and PCI-DES in patients
with PLAD coronary disease still remains a contro-
versial issue, especially with second-generation DES
for which further investigation is needed. Until
then, updated guidelines of scientiﬁc associations
and clinicians’ medical criteria deﬁne the appropri-
ateness of the method followed.Ioannis L. Matsoukis, MD
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Coll Cardiol Intv 2013;6:20–6.REPLY: Is CABG Superior to DES for Repeat
Revascularization in Patients With Isolated
Proximal LAD Disease?We thank Dr. Matsoukis and colleages for their letter
expressing an interest in our recent study (1).
Regarding the type of drug-eluting stents (DES)
(ﬁrst vs. second generation), 72% of the stents used in
the propensity-matched DES/coronary artery bypass
graft (CABG) pairs were second-generation DES, with
the others being ﬁrst-generation DES. When the pairs
were limited to second-generation DES compared
with CABG surgery, there were still no signiﬁcant
differences for mortality or for mortality/myocardial
infarction/stroke. Repeat revascularization rates were
again lower for CABG surgery, and the adjusted haz-
ard ratio (AHR) was very similar to the AHR for all
pairs (0.60 vs. 0.54 for all pairs).
It is possible that our results could have been
different if we had used cardiac mortality instead of
all-cause mortality, but unfortunately we did not
have access to that measure.
It is not true that CABG surgery was associated
with a signiﬁcantly lower rate when we looked at the
composite endpoint of mortality/myocardial infarc-
tion/stroke. As the letter states, we found the AHR tobe 0.96 (95% conﬁdence interval: 0.86 to 1.06),
which is not signiﬁcant because the conﬁdence
interval includes the number 1.*Edward L. Hannan, PhD
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Compared Correctly With
Clopidogrel in Non–ST-
Segment Elevation Acute
Coronary Syndrome?We read with great interest the paper by Montalescot
et al. (1) and the editorial by Ibanez and Dangas (2)
about prasugrel in non–ST-segment myocardial in-
farction (NSTEMI), and we appreciate the research on
this interesting issue. The ACCOAST (A Comparison of
Prasugrel at PCI or Time of Diagnosis of Non-ST
Elevation Myocardial Infarction) trial demonstrated
that pre-treatment with prasugrel in NSTEMI adds no
beneﬁt compared with initiating the drug after angi-
ography and also was associated with an increase in
bleeding events (3). In the same way, in the subgroup
of patients analyzed in the ACCOAST-PCI, the results
are concordant with the main study in terms of same
clinical outcome as well as a higher rate of bleeding
events (1).
